NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
GT Biopharma, Inc. GTBP
16 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
EPS · FY25
$-6.68
Dividend / sh · FY25
—
Payout · FY25
-1%
ROE · FY25
-1377.4%
Net margin · FY25
—
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
—
Revenue, FY2025 · full 16-year series below
Revenue
Net income
Per share
USD -6.68
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-1377.4%
Return on equity, FY2025
ROE
Operating margin—
Net margin—
Return on assets-459.6%
Each USD of equity lost 1377 cents this year.
Returned to shareholders
USD 229,000.00
returned in FY2025 · dividends + net buybacks
Dividends paidUSD 229,000.00
Net buybacks—
Share of profit-0.8%
Consecutive raises—
USD 229,000.00 in dividends went back to shareholders in a year without profit.
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.03B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 8.1M
total assets, end of FY2025
Total assetsUSD 8.1M
EquityUSD 5.8M
CashUSD 6.8M
Current ratio3.50×
Equity funds 71% of total assets.
History
16 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
Revenue $B
·
·
·
·
·
0.0
0.0
·
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.1
−0.0
0.0
−0.3
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
·
·
·
·
·
−0.0
0.0
−0.3
−0.1
−0.0
−0.0
−0.0
·
·
·
·
Income tax $B
·
·
·
·
·
·
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.1
−0.0
−0.0
−0.3
−0.1
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−6.68
−6.94
−5.64
−19.66
−2.06
−6.45
−0.01
−5.16
−8.60
119.91
−8.96
−0.04
−0.01
−0.01
−0.02
−0.03
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
−1
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−1377.4
−453.4
−79.1
−124.1
·
·
·
−197.1
−123.9
·
·
·
·
·
·
·
Shares out B
0.03
0.00
0.00
0.00
0.03
0.01
0.00
0.05
0.05
0.00
0.00
0.00
0.57
0.50
0.27
0.15
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
54 of 55
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 1 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed